VENTYX BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 USD | +4.91% |
|
+15.80% | +98.79% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 998.9 | 1,857 | 145.8 | 329.9 | - | - |
| Enterprise Value (EV) 1 | 998.9 | 1,539 | -155 | 122.3 | -9.001 | 219 |
| P/E ratio | -2.99 x | -15.8 x | -0.75 x | -1.67 x | -1.68 x | -2.63 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 4.95 x |
| EV / Revenue | - | - | - | - | - | 3.28 x |
| EV / EBITDA | - | -13.6 x | 0.75 x | -0.73 x | 0.05 x | -1.02 x |
| EV / FCF | -25.7 x | -15.5 x | 0.93 x | -0.82 x | 0.05 x | -1.07 x |
| FCF Yield | -3.9% | -6.43% | 108% | -122% | 1,883% | -93.6% |
| Price to Book | - | 5.28 x | 0.59 x | 0.91 x | 0.69 x | - |
| Nbr of stocks (in thousands) | 50,297 | 56,637 | 59,027 | 70,486 | - | - |
| Reference price 2 | 19.86 | 32.79 | 2.470 | 4.680 | 4.680 | 4.680 |
| Announcement Date | 3/23/22 | 3/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 66.7 |
| EBITDA 1 | - | - | -113 | -207.8 | -166.9 | -169.5 | -214.7 |
| EBIT 1 | - | -67.15 | -113.1 | -208 | -171 | -188.1 | -172.9 |
| Operating Margin | - | - | - | - | - | - | -259.24% |
| Earnings before Tax (EBT) 1 | - | -83.75 | -108.4 | -193 | -177.3 | -205.6 | -170.6 |
| Net income 1 | -28.17 | -85.3 | -108.4 | -193 | -167.7 | -192.6 | -162.8 |
| Net margin | - | - | - | - | - | - | -244.08% |
| EPS 2 | -14.16 | -6.650 | -2.070 | -3.300 | -2.795 | -2.781 | -1.782 |
| Free Cash Flow 1 | - | -38.91 | -99.05 | -167 | -149.5 | -169.5 | -205 |
| FCF margin | - | - | - | - | - | - | -307.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/20/21 | 3/23/22 | 3/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | -22.73 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -12.79 | -17.83 | -22.75 | -20.4 | -31.42 | -38.57 | -42.55 | -57.14 | -57.95 | -50.35 | -43.25 | -43.1 | -43.35 | -44.19 | -44.87 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.77 | -17.77 | -22.73 | -20.02 | -30.46 | -35.21 | -38.93 | -53.25 | -54.03 | -46.75 | -43.7 | -44.21 | -44.32 | -45.05 | -57.74 |
| Net income 1 | -12.77 | -17.77 | -22.73 | -20.02 | -30.46 | -35.21 | -38.93 | -53.25 | -54.03 | -46.75 | -41.24 | -41.32 | -41.96 | -43.15 | -44.87 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2540 | -0.4300 | -0.4500 | -0.3900 | -0.5900 | -0.6200 | -0.6800 | -0.9100 | -0.9200 | -0.7900 | -0.6671 | -0.6429 | -0.6443 | -0.6486 | -0.6750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/17/21 | 3/23/22 | 5/12/22 | 8/15/22 | 11/3/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/9/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 318 | 301 | 208 | 339 | 111 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -38.9 | -99 | -167 | -150 | -170 | -205 |
| ROE (net income / shareholders' equity) | - | - | -34.3% | -64.6% | -53.3% | -33.5% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 6.210 | 4.170 | 5.130 | 6.760 | - |
| Cash Flow per Share | - | - | -1.880 | - | - | - | - |
| Capex 1 | - | 0.26 | 0.28 | 0.51 | 1.13 | 1.8 | 3 |
| Capex / Sales | - | - | - | - | - | - | 4.5% |
| Announcement Date | 8/20/21 | 3/23/22 | 3/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
4.68
USD
Average target price
10.8
USD
Spread / Average Target
+130.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +98.79% | 330M | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
- Stock Market
- Equities
- VTYX Stock
- Financials Ventyx Biosciences, Inc.
